All Trials

A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adult women with recurrent/persistent ARID1A-mutated clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal carcinoma (≥50% histology; measurable disease; ≥2 prior cytotoxic regimens or platinum-resistant/refractory; no prior PARP inhibitor or temozolomide). Patients receive senaparib (oral PARP1/2 inhibitor) daily plus low-dose temozolomide on a 28-day cycle to assess objective response and safety.

ClinicalTrials.gov ID: NCT06617923

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women ≥18 with CLDN6-positive, advanced platinum‑resistant high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; ECOG 0–1) receive TORL‑1‑23, a CLDN6-targeted antibody–drug conjugate delivering MMAE to disrupt microtubules, given IV q3wk with prophylactic pegfilgrastim. Excludes non–high-grade epithelial histologies, primary platinum-refractory disease, prior CLDN6/MMAE-ADC exposure, active CNS disease, and grade ≥2 neuropathy.

ClinicalTrials.gov ID: NCT06690775

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after ≥4 cycles first-line platinum and 6 cycles second-line carboplatin doublet (ECOG 0–1) randomized to maintenance sacituzumab tirumotecan (TROP2-directed antibody–drug conjugate delivering a belotecan-derived topoisomerase I inhibitor) with optional bevacizumab versus standard-of-care maintenance with optional bevacizumab. Excludes platinum-resistant/refractory and non-epithelial/borderline histologies and patients with significant ocular disease, active IBD, uncontrolled CV/cerebrovascular disease, prior severe ILD/pneumonitis, or active CNS metastases.

ClinicalTrials.gov ID: NCT06824467

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E–driven cell-cycle progression, in adults with high-grade serous ovarian/fallopian tube/primary peritoneal cancer that is platinum-resistant and CCNE1/Cyclin E1–overexpressing. Eligible patients have had 1–4 prior regimens with prior bevacizumab (and mirvetuximab if FRα-positive) unless contraindicated; exclusions include non–HGS histology, primary platinum-refractory disease, and active CNS metastases.

ClinicalTrials.gov ID: NCT07023627

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer after prior systemic therapy are randomized to avutometinib (a dual RAF/MEK “clamp”) plus defactinib (FAK/Pyk2 inhibitor) versus investigator’s choice of pegylated liposomal doxorubicin, weekly paclitaxel, letrozole, or anastrozole. Requires measurable disease, ECOG 0–1, and known KRAS status; crossover to the combo is allowed at progression.

ClinicalTrials.gov ID: NCT06072781

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum‑resistant high‑grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer (1–3 prior lines; prior bevacizumab allowed), ECOG 0–1, measurable disease. Single‑arm regimen adds intermittent relacorilant (selective glucocorticoid receptor modulator to overcome taxane resistance) to nab‑paclitaxel and bevacizumab, given on a 28‑day cycle until progression/toxicity.

ClinicalTrials.gov ID: NCT06906341

Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Patients with Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adult women with measurable, recurrent platinum‑resistant epithelial ovarian cancer (ECOG 0–1; 0–3 prior lines in the platinum‑resistant setting; up to 5 prior lines total; BRCA status known/obtainable), excluding prior PD‑1/PD‑L1, CTLA‑4, CD47/SIRPα therapy or primary platinum‑refractory disease. Therapy combines pegylated liposomal doxorubicin and pembrolizumab with evorpacept (ALX148), a high‑affinity SIRPα‑Fc fusion that blocks CD47 to enhance macrophage‑mediated phagocytosis; treatment is every 21 days with possible maintenance pembrolizumab plus ALX148 after complete response.

ClinicalTrials.gov ID: NCT05467670

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Upfront therapy for adult women with measurable low-grade serous ovarian or primary peritoneal carcinoma who are not candidates for primary cytoreduction or have residual disease after suboptimal debulking. Patients receive avutometinib (dual RAF/MEK clamp) plus defactinib (FAK inhibitor) on a 3-weeks-on/1-week-off schedule with continuous letrozole (and ovarian suppression if pre/perimenopausal).

ClinicalTrials.gov ID: NCT06394804

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; prior bevacizumab and PARP inhibitor as indicated) are randomized to the CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd; cleavable linker to DXd topoisomerase I payload) given IV q3w versus investigator’s choice of weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan. Requires measurable disease, ECOG 0–1, available tumor tissue; excludes prior CDH6/DXd ADCs and patients with active ILD/pneumonitis or significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT06161025

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adult women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (platinum-sensitive or -resistant) with prior PARP inhibitor exposure, ECOG 0–1, and measurable disease. Patients receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT to downregulate HR/MYC programs) plus talazoparib (PARP inhibitor) in 28-day cycles; BRCA status known but not restricted.

ClinicalTrials.gov ID: NCT05071937